Table 5.
Cost-effectiveness and sensitivity analyses
| Control cost (€) | STEMI network cost (€) | Control 30-day mortality (%) | STEMI network 30-day mortality (%) | ICER*(€) mortality |
ICER* (€) QALYs |
|
|---|---|---|---|---|---|---|
| Scenario | ||||||
| Base case | 4355 | 495 | ||||
| Primary PCI | 8306 | 7874 | 7.7 | 5.6 | ||
| Fibrinolysis | 5956 | 5956 | 10.5 | 3.6 | ||
| Rescue PCI | 10 806 | 10 086 | 15.1 | 13.6 | ||
| No reperfusion | 8160 | 8160 | 13.4 | 15.1 | ||
| Alternative scenario | ||||||
| 30-day mortality | 2838 | 308 | ||||
| Primary PCI15 | 8306 | 7874 | 7.7 | 3.2 | ||
| Fibrinolysis16 | 5956 | 5956 | 10.5 | 6.2 | ||
| Rescue PCI17 | 10 806 | 10 086 | 15.1 | 6.2 | ||
| No reperfusion18 | 8160 | 8160 | 13.4 | 11.2 | ||
ICER calculated using different measures of effectiveness: mortality and QALYs, that is, €4355 for each additional life saved and €495 for each additional QALY.
ICER, incremental cost-effectiveness ratio; PCI, percutaneous coronary intervention; QALY, quality-adjusted life-year; STEMI, ST-segment elevation myocardial infarction.